Physician profile
Frank E Michener
NPI 1083675482
$949.26
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $104 · 2021: $137 · 2022: $102.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $146.36 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $136.54 | 2019 | |
| Janssen Pharmaceuticals, INC | $134.13 | 2019 | |
| Lundbeck LLC | $130.48 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $92.73 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $83.98 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $82.93 | 2019-2021 | |
| Adlon Therapeutics L.P. | $80.14 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $38.42 | 2022 | |
| Aytu Biopharma, INC. | $12.64 | 2019 | |
| Shire North American Group INC | $10.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Michener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.